Rituximab Dosing Guidelines for B‑Cell Malignancies

B‑Cell Non‑Hodgkin Lymphoma (NHL)

Standard dosing for all B‑cell NHL – Rituximab 375 mg/m² intravenously once weekly for 4 weeks when used as monotherapy, or the same dose administered on the day of each CHOP chemotherapy cycle (typically 6–8 cycles) for combination therapy. 1, 2, 3, 4
Young, low‑risk patients (aa‑IPI = 0) without bulky disease – Six 21‑day cycles of CHOP plus six rituximab infusions (375 mg/m²) given every 21 days. This regimen is the current standard of care with Level I, Grade A evidence. 1, 2, 3, 4
Young, low‑intermediate risk (aa‑IPI = 1) or bulky disease – Either R‑CHOP administered every 21 days for 6 cycles followed by radiotherapy to previously bulky sites, or the intensified R‑ACVBP regimen. 1, 2, 3
Young, high‑ or high‑intermediate risk (aa‑IPI ≥ 2) – Six to eight 21‑day cycles of CHOP combined with eight rituximab infusions (375 mg/m²) given every 21 days. 1, 2, 3
R‑CHOP every 14 days – A bi‑weekly schedule has not shown a survival advantage compared with the standard 21‑day interval. 1, 2
Patients aged 60–80 years – Six to eight 21‑day cycles of CHOP plus eight rituximab infusions (375 mg/m²) every 21 days. If a 14‑day R‑CHOP schedule is used, six CHOP cycles with eight rituximab doses are sufficient. 1, 2, 3, 4
Patients aged > 80 years – Rituximab 375 mg/m² combined with attenuated chemotherapy (R‑miniCHOP). 1, 2, 3

Pre‑chemotherapy rituximab – One dose of rituximab 375 mg/m² intravenously administered 1 day before each chemotherapy cycle. 5
Total number of infusions – Eight rituximab infusions administered over the course of treatment cycles constitute the recommended standard. 5
Eligibility criterion – Treatment is limited to patients whose leukemic blasts express CD20 in ≥ 20 % of cells. 5

Tumor‑lysis‑syndrome (TLS) prevention – In patients with a high tumor burden, specific prophylactic measures (e.g., hydration, uric‑acid lowering agents) should be implemented to avoid TLS. 1, 2, 3
Hepatitis B reactivation management – Patients with prior HBV exposure should receive antiviral prophylaxis or undergo periodic HBV‑DNA monitoring with prompt antiviral therapy if reactivation is detected. 1, 2, 3
Dose‑modification principle for curative intent – Dose reductions due to hematologic toxicity should be avoided whenever possible in patients treated with curative intent. 1, 2, 3
Prophylactic hematopoietic growth factors – Routine use of growth‑factor support is recommended for patients older than 60 years to mitigate chemotherapy‑induced neutropenia. 1, 2, 3

The American College of Rheumatology recommends a standard dosing of 1000 mg administered on days 1 and 15 for rheumatoid arthritis patients 6
For non-Hodgkin's lymphoma, the standard regimen is 375 mg/m² administered intravenously once weekly for 4 weeks 7
The European Renal Association recommends an induction therapy of 375 mg/m²/week × 4 weeks for ANCA-associated vasculitis 8
For idiopathic inflammatory myopathies, a dose of 1000 mg repeated on day 15, or 375 mg/m² once weekly for 4 weeks is recommended 6, 9

The American Society of Clinical Oncology recommends obtaining baseline immunoglobulin levels (IgG, IgM, IgA) before treatment 6
The Infectious Diseases Society of America recommends screening for hepatitis B and C, as well as latent tuberculosis before initiating rituximab therapy 6
The Mayo Clinic recommends checking IgA levels before administering IVIG (if IVIG is being used in combination therapy) 9

For elderly or infirm patients with indolent non-Hodgkin's lymphoma, the National Comprehensive Cancer Network recommends rituximab 375 mg/m² IV weekly for 4 doses 7
The Kidney Disease: Improving Global Outcomes initiative suggests age-based dose reductions may be needed in certain conditions, such as ANCA-associated vasculitis 8
For patients with renal impairment, the National Kidney Foundation recommends reducing the dose by 0.5 mg/kg/day for GFR <30 ml/min/1.73 m² in certain combination regimens 8

The American Society of Hematology recommends complete blood count with differential at baseline and at 2-4 month intervals 6
The European Society for Medical Oncology suggests clinical response assessment through disease-specific parameters 6
For lymphoma patients, the National Comprehensive Cancer Network recommends FDG-PET/CT for post-treatment assessment 6

The Centers for Disease Control and Prevention warns that severe infectious complications are a concern, particularly in immunosuppressed patients 6
The Food and Drug Administration reports that progressive multifocal leukoencephalopathy has been reported in patients treated with rituximab 6
The American Liver Foundation recommends monitoring for viral reactivation, particularly hepatitis B virus 7
The National Cancer Institute suggests considering prophylaxis for tumor lysis syndrome in high-risk patients 7